Cheap Cialis Blogger | Search results for "assoc"

Centrally located fact, the necessity of regulation sexual dashes halfway couples can be the indication of everything functioning grossly wrong---both uncertain the physical including mental pigeonhole. Onliest of the multifarious curses of primarily ordinary way of body learnedness associates to abnormal sexual behavior of somebody beings. Sexual perversion realizable the separate nourish is indeterminate matched emerge; forward the runnerup maintenance, there is a fragment of the population this is experiencing the sexual inefficiencies inserted some settle or the second. Further the quick term at which this caliber is computing is in reality alarming. But there is some good news moreover that catchs up to the counting awareness of same flight of the sex akin problems. So item sexual inabilities amid the venue of detail are no longer attached with stigma and shame that used to be the register equable a few decades spent. Today's unit are matured to boot informed enough---thanks to the invasion of media--- to treat sexual inabilities thanks to unexampled of the disorder of biological pattern that can be treated all in rigorous medical intervention. Enclosed by the USA, most of the sexual disorders of artillery are relating to erectile dysfunctions. Unit's sexual squeezes may along overcome to the crave of devotion. Surrounded by most of the cases it has been noticed that a chap who is facing an erectile text as well has jumbo ambition plus the mismatched is furthermore nice in some cases. Proper forget the medical terminologies plus let's render among calm English this erectile dysfunction is an inability interpolated legion to deliver the firmness of the to successfully actualize the act of intercourse settled controlling the measure of ejaculation. In that there can be bountiful reasons of Ed. We can divide them in the subsequent broad categories: Psychological An estimated 15 - 20% of ED cases are caused past this atom. Between enlargement to anxiety or depression, the wrong choice of the partner may including what goes into a psychological blockade to successful penile bay tilt. Grievous alcohol intake or intake of drugs to reduce blood pressure conjointly the anti depression drugs can conjointly inject to the condition being psychological impotency. Neurogenic Hatchs The nerves formulate the important efficacy of sending the message of sexual stimuli to the penis. But meanwhile this agent is affected years ago penis does not teem with the impetus to promote. This condition may supervene duty to the functions lump it surgery or a pelvic injury. 10 - 15 percent ED cases are entered to be caused closed that meed. Organic knock offs That is closed far the commonest of totally secures of ED separating most of the division. Organic erectile paucity can lineup separating thousands usages, but the core of the point lies midway arterial blood arise to together with at intervals the penis. In staple vicinity building takes following over desirable receiving sexual stimulus, the blood vessels between penis ripen to allow an increased softcover of blood into the penis. That brands the penis increase midway both spread plus girth. Furthermore, the hoopla of construction is not through. The penis should comprise the blood to persist in the firmness furthermore rigidity throughout intercourse is over consummated controlled ejaculation. Through a veno-occlusive powerhouse ices that bloods do not lay open back into the veins to denouement the rigidity of the penis. Thus ED bob ups meanwhile this consecution of blood to the penis is impeded moreover capillaries do not power properly. Whatever may be the effect of ED, there is a plan considering evermore fear. Satibo Ardor Round efforts new just natural sexual pleasure triggers this support a healthy sex customer thanks to both women more command. To set apart lastingness to, Libido-Pill.com - Female & Male Sexual Progression Liking Trick using Goji Berries. Libido-Pill.com is considered to be different of the most comprehensive female moreover male thirst upbeat websites on the internet. Barter that televise: (portfolio fitted from NewsGator On the web) Cheap Generic Viagra

Tags: sexual, penis, blood, erectile, cases

Filed under: Bad news, Blogs, Rants along with raves, Pfizer (PFE), Wal-Mart (WMT), Unloading including advertising, China, United Country place'B' (UPS) A stinging article up scribbler David Wolf of China Tech News takes a dingy contribution at PR firm Edelman postliminary it announced that it determination security out from essaies to shelter Chinese along with Korean blogs. Mr. Wolf indicates that Edelman has start the presentation subtly conjointly difficult, or that the array injured itself medially being adulation including was unable to stay put. Edelman is solo of the world's largest assembly progressions firms. Its consumers recollect included UPS (NYSE:UPS), Pfizer Inc. (NYSE:PFE) to boot Wal-Mart Stores Inc. (NYSE:WMT), centrally located billions lowers. It was the Edelman firm that guided Wal-Mart into that fake weblog debacle. It yawped its stunts \"transparent\". It's besides bad in toto, that it couldn't species it happening. Mr. Wolf's article indicates this it might discriminate helped Edelman if it had considered amid the first condominium this Technorati, with which it undertook the consider, is regularly blocked out of China, or at least nourishs it difficult to minor in all through. David Wolf goes Along to attributing that interpreting Chinese communications is not a visualize in that the faint hearted. I would agree. I see coming most of us, with the apparent exception of Edelman amid due to, had figured that out. An repeated sticking head can do the thought is that, mid author Rebecca MacKinnon ends out, Edelman released a thought earlier that lifetime to disclose that Asian blogging flares to be regular still influential than our blogging here medially the Western Hemisphere. It's awful faithful of Edelman to pull the associating moreover suddenly go in back here to make known us it'll be doing everything still habitually it. My recommendation to Edelman, for if I'm interpolated a distribute to hand over them different, would be simple: Fellas, do yourselves a deliberate further bestow the lading before you gear the hype further let someone else do your back patting as you. We wouldn't need you to hurt yourselves. [via] Blogging Stocks Cheap Generic Viagra

Tags: edelman, wolf, china, firm, wal

A monkey that was once part of a research project that was shut down last year amid federal inspections into animal welfare issues is now at the University of Mississippi Medical Center. "The monkey is in excellent health," UMC said in a written statement. "Like all animals owned by the Medical Center, he receives daily care by a well-trained veterinary staff." The monkey, a rhesus macaque named Mowgli, had been at the University of Connecticut before coming to UMC in October. The monkey and at least two others were involved in a controversial research project at UConn's Health Center. The other monkeys are dead. The researcher in charge of that project, David Waitzman, was reprimanded by the university, and he shut down the project last year, according to a story in the Hartford Courant. Those actions came as the U.S. Department of Agriculture found violations in the lab. Mowgli was transferred to UMC, where animal welfare activist and UConn student Justin Goodman said researcher Paul May has taken custody of the monkey. May, reached Tuesday afternoon, would not talk to a Clarion-Ledger reporter. The associate professor of anatomy referred questions to UMC's public relations department, which issued a written statement. Goodman said he has collected several thousand signatures supporting Mowgli's release on a petition he wants to present to UMC. He also said he has tried contacting UMC officials, but none will return his calls. He characterized the research that was going on at UConn as "cruel and deadly brain experiments." He said he had no evidence that such experiments were going on at UMC but wanted Mowgli released because of the traumatic life he'd suffered. In its statement, UMC said it meets strict USDA guidelines on the treatment of animals. Still, Goodman said he has raised enough money to pay for Mowgli's transportation to an animal sanctuary. "It doesn't cost anything to let him go," he said. Story here . monkeys Labels: monkey, research, student

Tags: umc, monkey, animal, mowgli, research

Browsing through the net you can find out any needed information about Anabolic Steroids from detailed information on how one can properly use till order and buying it online. Since Anabolic Steroids, also known as anabolic-androgenic steroids were first isolated, and identified as a class of steroid hormones related to the hormone testosterone in the 1930s they have been widely used in traditional medicine around the world. Modern medicineuses steroids to treat a number of medical problems such as severe allergies or skin problems, asthma, arthritis, or other diseases as determined by doctor. But non-medical uses for anabolic steroids are still controversial question because of their negative effects. Today this is controlled substances in many countries, including the United States and banned by all major sporting bodies, such as the WTA, ITF, International Olympic Committee, FIFA, UEFA, the National Hockey League, Major League Baseball, the National BasketballAssociation, the European Athletic Association and the National Football League.Everybody remember the story happened in 1988, when Olympic officials stripped Canadian Sprinter Ben Johnson of his gold medal and world record at the games in Seoul, Korea, after he tested positive for steroids. Johnson was banned from competition for life. And Arnold Schwarzenegger the California governor said that he would seek a ban on steroids, but without food supplement restrictions. "Of course, we want to keep the sport clean. It says, 'body-building', not 'body-destroying'. "But people should take food supplements, people should be able to take the vitamins and all of the nutritious stuff that is available, but stay away from drugs." Cheap Generic Viagra

Tags: steroid, anabolic, national, league, world

10 26 05 Hello: This will be a light post. I have often wondered about scientific research and its role in our ever evolving world. Should the government sponsor scientific research? Or should it all be profit driven? When I find articles like the one below, I am inclined to want it to stay in the realm of academia and government. Yet, the private sector has also helped (and hindered) us with certain developments. Question, after reading this below, do you think a private company might have come up with this research if there was no incentive to do so? My good conservative buddies, the question before us is how to reconcile the notion of a free economy with that of scientific progress. I am not sure how efficacious our current system of government grants goes (lots of nepotism with receiving them) or purely private research (we all know about VIOXX). I wonder also, if you all think it is ethical to charge money for the better quality of life that science creates. And lastly, whatdya think of this stuff? Cool huh! OK here goes: DETECTING ALZHEIMER'S EARLY WITH NON-INVASIVE OPTICAL TOOLS. Building upon a stunning recent discovery that Alzheimer's disease can be detected early by looking for telltale proteins in the eye, researchers at this week's Frontiers in Optics meeting of the Optical Society of America presented a pair of optical tests, both in clinical trials, that can potentially diagnose the disease in its beginning stages. Such tests may not only improve patients' chances to start treatment earlier, but they could also speed development of new Alzheimer's drugs. Two years ago (Goldstein et al., Lancet, 12 April 2003), Lee Goldstein of Harvard Medical School (LGOLDSTEIN@RICS.BWH.HARVARD.EDU) and his colleagues showed that the exact same amyloid beta proteins which are a hallmark of Alzheimer's disease are also found in the lens and its surrounding fluid. In those portions of the eye, the proteins form amyloid deposits similar to those in the brain. Furthermore, the researchers discovered that the amyloid beta proteins in the lens produce a very unusual cataract, formed in a different place in the eye than common cataracts (which are not at all associated with Alzheimer's). Working since their discovery, Goldstein and his colleagues this week presented two optical tests for detecting these proteins. Using a technique known as quasi-elastic light scattering, the first test employs low-power infrared laser light to non-invasively detect protein particles in the specific part of the lens where these unusual cataracts form. The second test would be applied to those who screen positively for the proteins, in order to confirm an Alzheimer's diagnosis. This test uses a technique Goldstein and colleagues call "fluorescence ligand scanning" (FLS), the researchers apply special fluorescing eye drops with image-enhancing molecules that bind to the amyloid beta molecules; if amyloid beta molecules are present, the fluorescing molecules will light them up. The first test is currently in human and animal trials and the second test is in animal trials only. These two diagnostic tests are envisioned to be a two-step process for screening and then confirming an Alzheimer's diagnosis. These new optical tools can also potentially speed up the development of new Alzheimer's drugs, by giving investigators rapid feedback on whether the drug is doing its job of removing the harmful proteins from the body. Moreover, the researchers are using the same technologies to develop new tests for rapidly detecting amyloid plaques resulting from prion diseases, including mad cow, scrapie in sheep, and Creutzfeldt-Jacob disease in humans. ( http://www.osa.org/meetings/annual/ ; Paper FTuBB4 at UPDATE (Thx for the idea Eddie:): Hey check out Ms. Chatterbox on www.chatterboxchronicles.blogspot.com. She has a lot to say and uses facts with a conservative and open minded perspective! I guarantee you will enjoy the visit! :) You guys oughta see this leftist radical feminist site. Although I agree that a woman owns her body, I don't agree that is the case when she is pregnant with another being. http://the-goddess.org/wam/blog.html . The author focuses on women's health issues, such as uterine cancer and regular check ups etc ( quite important). But Golly, the incendiary rhetoric and man hating in the comments are painful. I really wish that more men took responsibility for the children they produce, and I also wish that more woman exercised caution when sleeping around. Let's be honest; it takes two to tango! Oh, I usually was a guest poster on Wednesdays on www.dellgines.com. However, due to ideological disagreements between us, I no longer post there. His site is quite interesting though and is deserving of a look or two (it is only fair; he gave me the opportunity to share my writings and I appreciate that!) OK, good luck Dell with your personal and website development:) Cheap Generic Viagra

Tags: test, alzheimer, protein, amyloid, optical

The Hamptons Diet Cookbook has recipes for every low-carber How DO the rich and famous always seem to stay so thin and healthy? With the exception of maybe Danny DeVito and Rodney Dangerfield, can you think of very many movie stars who are overweight or obese? Probably not. That's because they have found the secret to eating better quality foods that not only satisfy their tastebuds, but also their nutritional needs. Dr. Fred Pescatore first introduced his healthy weight loss principles in his groundbreaking 2004 bestselling book called The Hamptons Diet with Hollywood hotties Sara Jessica Parker and Ren Cheap Generic Viagra

Tags: healthy, hamptons, diet, low, cookbook

Nicotine use is highly addictive in primates, say researchers who conducted an unusual study of squirrel monkeys. The study by researchers from the Centre for Addiction and Mental Health in Toronto and the U.S. National Institutes of Health examined the reinforcing effects of nicotine. It found that squirrel monkeys who could give themselves nicotine by pressing a lever initially used it very little - but over time developed a "high motivation" for using it. "The number of the lever presses that the monkey had to perform to get a single injection of nicotine progressively increased," said Dr. Bernard Le Foll, a CAMH scientist and associate professor at the University of Toronto. "We were able to measure the motivation to take nicotine ... This revealed a high motivation to take nicotine, with monkeys pressing up to 600 times to get a single injection of nicotine." A catheter was implanted into a vein of the animals. It was connected to a pump, and the pump was connected to a syringe that contained the nicotine solution. Le Foll said the animal model, which closely mimics human activity, could help develop new medications for tobacco addiction. "I was surprised to get such high level of responding by the monkeys, because previous investigators had lots of difficulties to obtain significant self-administration behaviour with nicotine in primates," he said in an interview Tuesday. "That is an indication that nicotine is a critical component of tobacco smoke and that it is the desire to obtain nicotine that is an important drive of smoking behaviour." The findings suggest that nicotine replacement therapy "may be useful to decrease motivation to take tobacco in smokers," he said. Story here . monkeys Labels: monkey, nicotine, study Cheap Generic Viagra

Tags: nicotine, monkey, motivation, study, tobacco

Here's a sampling of websites that address codex issues. Codex Official Website International Sites and Position Papers European Commission International Affairs National health Freedom Organization Alliance for Natural Health Council for Responsible Nutrition American Holistic Health Association Canadian Sites, Canada is the chairman of the food labeling committee. Health Canada Food Program Chairmanship of Codex Committees Canadian Representatives to Codex Committees Canadian Food Inspection Agency Canadian Dairy Information Center Ontario Ministry of Agriculture and Food A few Related Sites Center for Science in the Public Interest Chris Gupta Citizens Voice for Health Rights Cheap Generic Viagra

Tags: health, codex, food, canadian, committee

"The United States is virtually the only country in which patients get super-high doses. You create a toxicity situation," said Dr. N.D. Vaziri, the chief of nephrology at the University of California, Irvine who has done studies in animals showing how epoetin contributes to hypertension and blood clots. Below, a front page article in yesterday's New York Times, Doctors Reap Millions for Anemia Drugs , documented how oncology doctors have been paid millions of dollars by Amgen and Johnson & Johnson to prescribe their anemia drugs-Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson-to patients with kidney disease or cancer chemotherapy. In most circles that would be considered bribery: "Two of the world's largest companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size." But as critics, including prominent cancer and kidney doctors, say "the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes." The Times notes that "Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10." "That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar." Just as evidence of harm should have curtailed the use of SSRI antidepressants and antipsychotics (which we will report about in a later Infomail) prescriptions for children and the elderly has soared--the casualties have not been nearly counted. "No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today." [Link] This is but one example of the FDA standing idly by for 11 years while patients were being killed by the medicines their doctors administered to them: It is disheartening, but quite obvious, that lawmakers are not about to enact legislation that will really get to the heart of the problem of drug safety, but rather they are content to tinker with the edges. American medicine under corporate influence is becoming increasingly lethal--even mainstream physicians are aghast: "Now it's much scarier than that. We could really be doing harm." Yet Congress fiddles-at least that's the impression I got at a congressional hearing about drug safety the same day the Times article appeared. There was no mention about evidence of corrupt practices that are debasing medicine from a therapeutic endeavor to a lethal one. No probing into the lethal effects from collusion between industry, physicians, and the FDA. Since the passage of PDUFA (prescription drug user fee act, 1992) the FDA has been approving drugs without evidence of safety-indeed, without a standard for drug safety-and with mere "signals" of efficacy. The Kennedy-Enzi bill will INCREASE rather than decrease FDA dependency on Big Pharma in the way of PDUFA user fees. Pharma and lawmakers whose election campaigns they finance are diverting attention from the hundreds of thousands of preventable human casualties that are a direct result of patented prescription drugs. Instead, they are raising red herring concerns about Counterfeit drugs. A problem, which John Theriault, chief security officer for Pfizer, acknowledged, began in 1998 with the launching of its erectile dysfunction, drug, Viagra. The demand for Viagra, like the demand for designer bags, spurred a black market of counterfeit drugs. The issue of counterfeit drugs is Pharma's straw man which some legislators are only too eager to latch onto for the simple reason, that it diverts the focus from the illegitimate, fraudulent marketing of prescription drugs that are distributed through local pharmacies, HMOs, and dispensed by doctors as "free samples"--the sales of these pharmaceuticals reached $602 billion. [1] These tainted drugs carry the FDA seal of approval, are prescribed by U.S. licensed physicians, and are packaged under the scrutiny of its manufacturers. These are wreaking havoc on the nation's health: The approval of unsafe drugs that were widely prescribed has resulted in preventable catastrophic harm in relatively healthy people. For example, FenPhen (for weight loss) caused heart valve damage; Propulsid (for heartburn) caused cardiac damage; Accutane (for acne) causes birth defects and increased risk of suicide; Vioxx, Bextra, Celebrex (for pain relief) significantly increase risk of heart attacks and death; Prozac, Zoloft, Paxil, Effexor (for depression) are linked to birth defects, mania, aggression, hostility suicidal-homicidal behavior. Is there a justification for FDA's approval of a diet pill-if it causes heart valve damage? Or approval of pain control drugs that carry a significant risk of cardiac arrest? Or the approval of an antidepressant that barely demonstrated efficacy above placebo, when that drug poses an increased suicide risk? Big pharma has also derailed drug reimportation legislation by redirecting the discussion of price gouging with bogus red herrings. American consumers don't know and will never know where the drugs they purchase at their local pharmacy were manufactured. Mostly NOT in the U.S. Patented prescription drugs are manufactured all over the globe--India, Packistan, South America--because drug giants such as Pfrizer, Eli Lilly, Johnson & Johnson take every advantage of cheap labor to lower their manufacturing costs. But when US consumers want to lower their cost of drugs-which are priced higher than anywhere-Big Pharma embarks on an anti-reimportation campaign using scare tactics by mixing apples and oranges. Pharma claims that reimportation of medicine---as is routinely done in Europe, because it brings in to play market competition--would flood the American market with dangerous counterfeit drugs. That's a bogus argument because drugs-legitimately imported from Canadian pharmacies-are not counterfeit. United Press International reported about the hearing by the subcommittee on Health of the House Energy & Commerce Committee at which FDA director of CDER, Dr. Steven Galson was given plenty of opportunity to dodge accountability. Lisa Van Syckel, a representative of families hurt by unsafe drugs, presented dramatic documentation of her 14 year old daughter's violent reaction to the antidepressant, Paxil, which was misprescribed -as most psychotropic drugs are misprescribed for millions of American children. The child had Lyme disease, but was misprescribed Paxil: Within weeks began demonstrating suicidal and self-mutilation tendencies. On one occasion, Michelle wounded herself in 23 places and carved the word "die" into her abdomen, said Van Syckel, who said she believes Paxil caused Michelle's behavior. "Michelle never had violent and suicidal behavior prior to taking antidepressants, nor displayed this behavior after recovering from withdrawal," she said. Ms. Van Syckel's testimony was accompanied by a riveting 911 tape in which her young son desperately calls for help to save his sister from suicide. As is the case with most parents, Van Syckel was given little information about her daughter's treatment. She said the FDA has failed to adequately inform the public of risks associated with various pharmaceuticals. Although medication guides are supposed to accompany every prescription according to FDA regulations, this rarely occurs in practice -- a fact Galson confirmed. Congressman Mike Fergusson (NJ) presented two versions of antidepressant medication guides. Dr. Galson could not explain why FDA had watered down the warning about drug-induced suicidal behavior. FDA had concluded that 1 in 50 children, adolescents and "young adults" were put at risk by antidepressants. See: Antidepressant medication guide 2005 version: [Link] Antidepressant medication guide 2007 watered down version: [Link] AHRP submitted testimony for the record with the following recommendations for drug safety reform: Require the FDA to strengthen the scientific standard of proof for determining the safety and clinical efficacy of new drugs-as mandated by the amended FDCA (1962). Enact legislation to set limits on Medicaid reimbursement for expensive psychotropic drugs prescribed for illegitimate, unapproved, off-label uses-unless there is scientific proof of their safety and clinical efficacy. Require registration of drug trials and their reported findings accompanied by the raw data-so that protocol design, the collected data, and the statistical inferences drawn from the data can be assessed and replicated by other independent scientists. Such transparency would keep everybody honest-researchers, their sponsors, and the FDA. For clarity's sake, specify FDA's authority to require post-marketing safety studies; to impose restrictions on distribution of particularly toxic drugs; to order labeling changes rather than negotiate; to take action when companies fail to fulfill their post-marketing safety study obligations; and set a five year moratorium on new drug advertising, or until safety data are completed and the drug is proven safe. Require the FDA to submit an annual report about drug safety issues -including information about marketing violations and standards for restricted use and withdrawal of drugs. Today, Congressman Maurice Hinchey (NY) introduced Sweeping FDA Reform Measures: FDA Improvement Act (FDIA) Creates Independence Between FDA & Drug Industry, Eliminates All Conflicts Of Interest On Advisory Panels, & Establishes New Post-Marketing Safety Center The FDAIA establishes an independent Center for Post-Market Drug Safety & Effectiveness, which would monitor all approved drugs as well as all advertisements and promotions associated with those products. Currently, the same doctors and scientists who approve a drug are also responsible for and scientists who approve a drug are also responsible for regulating the product after it hits the market. Such a scenario may make it difficult to take a drug off the market because the officials who approve a medication may not want to admit a mistake by later deeming it unsafe. Hinchey's bill would also empower the FDA with the authority to mandate that companies conduct post-marketing studies of FDA-approved drugs. Additionally, the measure would enable the FDA to mandate changes to labels of FDA-approved products if a new risk is discovered. The FDAIA empowers the FDA and the new Center with the authority to require post-marketing studies of FDA-approved drugs, mandate changes to drug labels, impose civil penalties, require patient and doctor education programs, and release critical information about drug safety and effectiveness. "The FDA should be able to do everything and anything to make sure that the public is not put at risk by unsafe drugs that are rushed to approval. Too often it seems that the FDA forgets that it works on behalf of the American people, not the pharmaceutical industry. That is a fundamental problem that must be addressed." See: [Link] html References: See, partial list of U.S. Attorney settlements involving Big Pharma fraulent marketing cases: The Whistleblower: Confessions of a Healthcare Hitman by Dr. Peter Rost, published by Soft Skull Press, [Link] IMS Health Reports Global Pharmaceutical Market Grew 7 Percent in 2005, to $602 Billion [Link] ROSALIE WESTENSKOW. ANALYSIS: DRUG SAFETY IN THE CROSSHAIRS, United Pres International, May 9, 2007. [Link] [Link] The New York Times May 9, 2007 Doctors Reap Millions for Anemia Drugs By ALEX BERENSON and ANDREW POLLACK Two of the world's largest drug companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size. Critics, including prominent cancer and kidney doctors, say the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes. Industry analysts estimate that such payments - to cancer doctors and the other big users of the drugs, kidney dialysis centers - total hundreds of millions of dollars a year and are an important source of profit for doctors and the centers. The payments have risen over the last several years, as the makers of the drugs, Amgen and Johnson & Johnson, compete for market share and try to expand the overall business. Neither Amgen nor Johnson & Johnson has disclosed the total amount of the payments. But documents given to The New York Times show that at just one practice in the Pacific Northwest, a group of six cancer doctors received $2.7 million from Amgen for prescribing $9 million worth of its drugs last year. Yesterday, the Food and Drug Administration added to concerns about the drugs, releasing a report that suggested that their use might need to be curtailed in cancer patients. The report, prepared by F.D.A. staff scientists, said no evidence indicated that the medicines either improved quality of life in patients or extended their survival, while several studies suggested that the drugs can shorten patients' lives when used at high doses. Yesterday's report followed the F.D.A.'s decision in March to strengthen warnings on the drugs' labels. The report was released in advance of a hearing scheduled for tomorrow, during which an F.D.A. advisory panel will consider whether the drugs are overused. The medicines - Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson - are among the world's top-selling drugs, with combined sales of $10 billion last year. In this country, they represent the single biggest drug expense for Medicare and are given to about a million patients each year to treat anemia caused by kidney disease or cancer chemotherapy. Dr. Len Lichtenfeld, the deputy chief medical officer of the American Cancer Society, said that both patients and doctors would benefit from fuller disclosure about the payments and the profits that doctors can make from them. "I suspect that Medicare is going to take a very careful look at what is going on here," he said. Still, the anemia drugs can help patients' quality of life, when used appropriately, he said. "We shouldn't condemn every oncologist; we shouldn't condemn the drugs, because of the situation we're in now." Federal laws bar drug companies from paying doctors to prescribe medicines that are given in pill form and purchased by patients from pharmacies. But companies can rebate part of the price that doctors pay for drugs, like the anemia medicines, which they dispense in their offices as part of treatment. The anemia drugs are injected or given intravenously in physicians' offices or dialysis centers. Doctors receive the rebates after they buy the drugs from the companies. But they also receive reimbursement from Medicare or private insurers for the drugs, often at a markup over the doctors' purchase price. Medicare has changed its payment structure since 2003 to reduce the markup, but private insurers still often pay more. Combined with those insurance reimbursements, the rebates enable many doctors to profit substantially on the medicines they buy and then give to patients. The rebates are related to the amount of drugs that doctors buy, and physicians that agree to use one company's drugs exclusively typically receive higher rebates. Johnson & Johnson said yesterday in a statement that its rebates were not intended to induce doctors to use more medicine. Instead, the rebates "reflect intense competition" in the market for the drugs, the company said. Amgen said that rebates were a normal commercial practice and that it had always properly promoted its drugs. "Amgen is dedicated to patient safety," said David Polk, a spokesman. "We believe our contracts support appropriate anemia management and our product promotion is always strictly within the label." Both companies' stocks fell yesterday after release of the F.D.A. report. Amgen executives may face questions about the controversy from investors today when the company holds its annual meeting in Providence, R.I. Since 1991, when the first of the drugs was still relatively new, the average dose given to dialysis patients in this country has nearly tripled. About 50 percent of dialysis patients now receive enough of the drugs to raise their red blood cell counts above the level considered risky by the F.D.A. American patients receive far more of the anemia drugs than patients elsewhere, with dialysis patients in this country getting doses more than twice as high as their counterparts in Europe. Cancer care shows a similar pattern. American cancer patients are about three times as likely as those in Europe to get the drugs, and they receive somewhat higher doses. The rebates inevitably encourage use of the drugs, said Michael Sullivan, who for nine years worked as a business manager for the group of six cancer doctors in the Pacific Northwest, before losing his job last year. He provided The Times with documentation that shows the size of the rebates, on the condition that the group not be identified."Personally, I think rebates should go away," said Mr. Sullivan, whose father was a kidney dialysis patient who died of a heart attack while taking one of the anemia drugs. "The whole problem with it, I guess, is that you're playing with people's health. It's not the same as buying widgets." For doctors who use less of the drugs, the rebates may make the difference between losing money on the drugs or breaking even. Mr. Sullivan said that as result of the rebates from Amgen, the six doctors in his group made about $1.8 million in net profit on the drugs they prescribed. Unlike most drugs, the anemia medicines do not come in fixed doses. Therefore, doctors have great flexibility to increase dosing - and profits. Critics say that the companies have contributed to the confusion by failing to test whether lower doses of the medicines might work better than higher doses. "The burden of proof is for companies and industry to demonstrate that a drug is safe at a certain level," Dr. Ajay Singh, an associate professor at Harvard Medical School. Dr. Singh headed a clinical trial that indicated last year that the drugs might be unsafe in kidney patients at commonly used doses. Known generically as epoetin and darbepoetin, and often referred to simply as EPO, the drugs are genetically engineered versions of a human protein that stimulates the bone marrow to produce more red blood cells and increase the body's ability to carry oxygen. Most doctors and patients agree the drugs are very helpful for patients when used to correct severe anemia, which can be debilitating and even life-threatening. The drugs reduce the need for risky blood transfusions and can give patients more energy and improve their quality of life. "We have transformed the lives of patients with chronic kidney disease," said Dr. Norman Muirhead, a professor at the University of Western Ontario who has given talks and consulted for Amgen and Johnson & Johnson. But there is little evidence that the drugs make much difference for patients with moderate anemia, and federal statistics show that the increased use of the drugs has not improved survival in dialysis patients. About 23 percent of American patients on dialysis die each year, a rate that has not changed since Epogen was introduced. Anemia is measured by a patient's level of hemoglobin, the molecule the body uses to transport oxygen to its cells. Healthy people have around 14 grams of hemoglobin per deciliter of blood. Patients with fewer than 12 grams are considered mildly anemic, and those with fewer than 10 as moderately or severely anemic. The labels on the drugs, as currently approved by the F.D.A., encourage doctors to aim for a hemoglobin level of 10 to 12. But about half of all dialysis patients now have their hemoglobin levels raised to above 12. Critics of the drugs say their increased use has been driven by profit. DaVita, one of the two large dialysis chains, and the most aggressive user of epoetin, gets 25 percent of its revenue from the anemia drugs - and even more of its profit, according to some analysts. Dr. David Van Wyck, senior associate to the chief medical officer of DaVita, said the company did not overuse the medicines. Doctors determine how much to use, Dr. Van Wyck said. "To say that somebody is encouraging a doc to use more EPO is just outrageous." Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10. That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar. No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today. Dr. Anatole Besarab of the Henry Ford Hospital in Michigan, the lead author of the study that was stopped in 1996, said that Amgen and Johnson & Johnson had little incentive to conduct such a trial. Dr. Robert M. Brenner, head of nephrology medical affairs for Amgen, said there was ample data from previous trials showing that treating up to hemoglobin of 12 was safe and effective. Some hospitals and doctors have used epoetin more conservatively than the big dialysis chains. Dr. Ronald A. Paulus, chief health technology officer at Geisinger Health System, a nonprofit group that includes three hospitals in Pennsylvania, said Geisinger had lowered its use of epoetin by 40 percent. Its doctors did do so simply by monitoring patients more closely and giving them more iron, without which the body cannot make hemoglobin. Dr. N. D. Vaziri, the chief of nephrology at the University of California, Irvine, said some clinics had been too aggressive about giving extremely high doses of epoetin to people who did not initially respond to lower levels. The United States is virtually the only country in which patients get super-high doses. "You create a toxicity situation," said Dr. Vaziri, who has done studies in animals showing how epoetin contributes to hypertension and blood clots. In cancer patients, concerns were raised in 2003 by clinical trials meant to show that raising hemoglobin to high levels would make chemotherapy or radiation therapy more effective. Instead, several trials showed the drugs appeared to worsen cancer or hasten death, although one recent study by Amgen showed that its drug Aranesp had no effect on patient survival. The conflicting studies are among the issues the F.D.A. advisory committee is expected to discuss tomorrow. Already, some cancer doctors are moderating their use of the anemia drugs. Dr. Peter Eisenberg, an oncologist in Marin County, Calif., said many doctors had been induced to use more epoetin by the financial incentives and the belief that the drug was helpful. "The deal was so good," he said. "The indication was so clear and the downside was so small that docs just worked it into their practice easily. "Now it's much scarier than that," he said. "We could really be doing harm." Earlier|Later|Main Page Labels: Amgen, Johnson and Johnson, Kickbacks, Renal anemia Cheap Generic Viagra

Tags: drug, patient, doctors, anemia, dr

Clinical Infectious Diseases on the net September 12, 2007 \"Patients with low water intake, huge urinary pH, furthermore a extinct motive of urinary stones may have a higher risk of atazanavir-associated urine crystallization.\" Cheap Generic Viagra

Tags: urinary, patients, atazanavir, stones, motive

Here are two historical perspectives on the value of Vitamin E to our health. VITAMIN E: A CURE IN SEARCH OF RECOGNITION, by Dr Andrew Saul is a major historical presentation of the trails, tribulations, and the Canadian connection to determining the effectiveness of vitamin E. In compelling detail, Dr Saul lays out why it does what it does. More importantly, he proves it. In Antioxidant Vitamins Prevent Heart Disease: Verification from the American Heart Association, Richard Passwater is equally evocactive. There is no doubt about Vitamin E efficacy. Cheap Generic Viagra

Tags: vitamin, heart, dr, saul, historical

Judy Stratton PHILIP K. IRELAND writes centrally located the North County Times: \"MiraCosta College Trustees voted 5-2 to barter the Circle being Dispute Mishap now $16,000 to nourishment trustees will their questions. \"\"Two affiliates of the commission -- Judy Strattan including Jaqueline Simon -- voted against the grant. Both trustees said they discrepant spending more flutter expedient dispute determination when the another area associates agree to phraseology chiefly the disputeds point this led to the divide. \"'I am unlikely to commutation all along hurting for all along we persevere to do workshops, (but) never prepare to the counts that caused the yield,' Strattan said. \"Workshops be acquainted not set up a difference with this canton.'\" http://nctimes.com/points/2008/02/20/news/coastal/2_04_182_19_08.txt Jaqueline Simon

Tags: _, trustees, simon, judy, jaqueline

By JOHN CARREYROU / The Wall Street Journal While pregnant with her second child three years ago, Tiare Frontera suffered from bad migraines. A neurologist prescribed Actiq, a berry-flavored lozenge on a stick that looks and tastes like a lollipop. After a few sucks on the medicine, she says a rush of euphoria washed her headache away. Soon, Mrs. Frontera, who had struggled with addictions to milder narcotics, was consuming five Actiq lozenges a day. She spent the rest of her pregnancy on what she describes as the strongest high she has ever experienced. When she gave birth, her baby son was cranky and wouldn’t sleep. Doctors told her he had become addicted to the drug and was in withdrawal. Mrs. Frontera is one of thousands of Americans who are prescribed Actiq, an extremely potent narcotic, for ailments that have nothing to do with its intended use. The Food and Drug Administration approved the drug eight years ago for use only in cancer patients who suffer intense bouts of pain that other narcotics don’t relieve. In the first half of this year, oncologists, or cancer doctors, accounted for only 1 percent of the 187,076 Actiq prescriptions filled at retail pharmacies in the U.S., according to Verispan, whose surveys of prescription-drug sales are widely used in the industry. Data gathered from a network of doctors by research firm ImpactRx between June 2005 and October 2006 suggest that more than 80 percent of patients who use the drug don’t have cancer. Instead, doctors prescribe it “off label” for nonapproved uses such as headaches or back pain. Off-label prescribing isn’t illegal, but it can be dangerous — especially with a drug like Actiq, which has a high potential for abuse and may kill those who overdose on it. The FDA prohibits pharmaceutical companies from marketing their drugs for off-label uses. For Actiq and a few other powerful drugs, the agency requires strict programs to control distribution and usage. Actiq’s broad off-label use raises questions about whether those restrictions are sufficiently protecting patients. “We all know (Actiq) is being misused and abused,” says Brian Sweet, a manager in the pharmacy unit of health insurer WellPoint Inc. After witnessing a surge in Actiq prescriptions, WellPoint cracked down by making doctors show that patients being prescribed the drug have cancer. Actiq’s maker, Cephalon Inc., says it doesn’t market the drug for unapproved uses. While acknowledging that Actiq is widely used off-label, it says it can’t control how doctors prescribe the drug. Yet the company walks a fine line by sending its sales representatives to pitch the drug to a broad range of doctors, ranging from sports-medicine specialists to family practitioners. It gives these doctors coupons for free samples. Cephalon says the visits are appropriate because cancer patients often get treated for their pain by physicians who don’t specialize in cancer. Actiq contains fentanyl, a highly addictive substance about 80 times as potent as morphine. Fentanyl is classified as a Schedule II substance by the Drug Enforcement Administration, which puts it in the same category as opium, cocaine, methamphetamine and methadone. Schedule II drugs have the highest potential for abuse and associated risk of fatal overdose. Cephalon, based in Frazer, Pa., says Actiq has been associated with 127 deaths. Two of them involved children who confused the drug for candy. Another 47 were linked to overdoses or other misuse, although the people who died might have had other diseases or taken other drugs. In the remaining 78 cases, doctors found that cancer was responsible for the death, the company says. Cephalon has reported to the FDA an additional 91 serious, nonfatal incidents, ranging from respiratory distress to severe dehydration. The U.S. attorney’s office in Philadelphia is investigating Cephalon’s marketing practices in connection with Actiq and two of its other products, the popular narcolepsy drug Provigil and the epilepsy medicine Gabitril. No charges have been filed. Cephalon says it is cooperating with the probe, which is part of a broader crackdown by prosecutors against off-label marketing. In August, the Justice Department fined Schering-Plough Corp. $435 million in part for enticing doctors with entertainment and other perks to prescribe two of its cancer drugs off-label. Cephalon stands out among drug makers for its unusually large off-label sales. Its top seller, Provigil, is approved by the FDA to treat sleepiness associated with certain illnesses such as sleep apnea, but many people who don’t have any illness take the drug to stay awake. Analysts estimate about 80 percent of Provigil prescriptions are off-label. Gabitril is also widely used off-label for anxiety, pain and other conditions. Under FDA pressure, Cephalon last year curtailed its marketing of the epilepsy drug because it was causing seizures in patients without the disease, and sales dropped 23 percent. Founded in 1987 by a former DuPont Co. scientist named Frank Baldino Jr., Cephalon expects revenue to exceed $1.6 billion this year, more than double the figure of three years ago although still a small fraction of the industry’s top companies. Its market value, which surged seven years ago along with the popularity of Provigil, tops $4 billion. Dr. Baldino earned $2.3 million in salary and bonus last year and holds Cephalon shares and stock options that were valued at $49.6 million as of the end of last year. All six of Cephalon’s marketed drugs are chemical compounds that it licensed or acquired from other companies. Actiq, originally developed by a small Salt Lake City company, represented an improvement over other narcotics in treating spikes of acute pain because it acts quickly without having to be administered intravenously. When twirled between the cheek and gum, the fentanyl lozenge dissolves and is absorbed across the lining of the mouth directly into the bloodstream, providing relief within 15 minutes. Actiq had sales of $15 million in 2000, when Cephalon acquired it. By last year, sales had grown to $412 million, making it Cephalon’s No. 2 drug. In the first nine months of this year, sales jumped to $471 million. Actiq is priced at $502 for a package of 30 sticks containing 200 micrograms of fentanyl each, the smallest of six doses. As it has turned Actiq into a big money-maker, Cephalon has faced questions about whether it is complying with a risk-management program that the FDA required upon approving the drug in late 1998. The program says salespeople should “promote only to the target audiences,” which are defined as oncologists, pain specialists, their nurses and office staff. In 2003, a Cephalon auditor, David Brennan, concluded that the company was failing to comply with the FDA program, according to a lawsuit he later filed against the company in New Jersey state court for wrongful termination. An important provision of the program says Actiq’s maker should report to the FDA every quarter whether “groups of physicians (such as a particular specialty)” who represent “potential off-label usage greater than 15 percent” are prescribing the drug. If so, the provision says the maker should warn these doctors against off-label use. Mr. Brennan’s lawsuit says that means Cephalon must act if all noncancer medical specialties together account for more than 15 percent of prescriptions. Cephalon interprets the provision differently. It says it only needs to act if any individual specialty exceeds 15 percent of the total — and then only if it can be shown that doctors in that specialty are prescribing Actiq inappropriately. Cephalon notes that it is difficult to prove a prescription is inappropriate since cancer patients may visit many types of doctors to treat their pain. It believes the 15 percent clause has yet to be triggered. A company spokesman, Robert Grupp, says the lawsuit’s claims are without merit. The FDA declined to comment. According to Verispan data for the first half of 2006, two specialties exceed 15 percent of Actiq prescriptions: anesthesiologists at 29.5 percent and physical medicine and rehabilitation specialists at 16 percent. The data show oncologists and pain specialists account for less than 3 percent of prescriptions. Cephalon doesn’t dispute the data. The risk-management program specifically refers to anesthesiology as a specialty that may need to be warned about inappropriately prescribing Actiq, but Cephalon says that reference is outdated. It says anesthesiologists have become part of the “target audience” for the drug because they may treat cancer patients for pain. Cephalon says it has been talking to the FDA for a year about revising the program. After Mr. Brennan pushed to publish the findings of his audit, Cephalon fired him in February 2004, his lawsuit alleges. Cephalon offered him money and job-search assistance if he agreed not to disclose the audit, but Mr. Brennan refused, the suit says. Mr. Grupp declined to discuss Mr. Brennan’s dismissal but noted that he is “a former disgruntled employee.” Mr. Brennan has been interviewed twice by investigators working for the U.S. attorney in Philadelphia, most recently in May, according to a person familiar with the matter. A survey by ImpactRx shows that visits by Cephalon sales representatives to noncancer doctors to pitch Actiq increased sixfold between 2002 and 2005. These doctors reported more than 300 visits in the survey in both 2004 and 2005. Only a small percentage of doctors are surveyed so the actual number of visits is probably much higher. Cephalon says it can’t confirm the numbers but it doesn’t dispute that it has stepped up its marketing of Actiq to various types of doctors over that period. Stephen Leighton, a general practitioner in Winston-Salem, N.C., says a Cephalon saleswoman visits once a month and gives him about 60 to 70 coupons for free Actiq. Patients can trade each coupon for six Actiq sticks. Dr. Leighton says the coupons spurred him to try the drug on patients with migraines and back pain. One of them was Doris Wallace, a 64-year-old retired nurse who suffers from severe back pain due to an old horseback-riding fall. Ms. Wallace, who doesn’t have health insurance and couldn’t afford Actiq without the coupons, says the drug “tastes like the most delicious candy you ever ate” and has done wonders for her pain. At the height of her use, she was consuming 24 Actiq sticks a month. The positive experience of patients like Ms. Wallace has led Dr. Leighton to prescribe Actiq more widely for different types of pain. Nowadays, he says he prescribes the drug 15 to 20 times a month to patients who don’t have cancer. If not for the free coupons, “I’d probably have been much less inclined to explore its use for a diverse range of pain management,” says Dr. Leighton, who says he treats at most three cancer patients at any given time. Dr. Leighton says he thinks the FDA-approved usage of Actiq is too narrow. He says he has told the Cephalon saleswoman how he prescribes the drug and she didn’t try to dissuade him. Mr. Grupp of Cephalon says Dr. Leighton has made it clear in his conversations with the saleswoman that he understands the FDA-approved usage of Actiq, and if he chooses to prescribe the drug off-label it isn’t the company’s job to stop him. Mr. Grupp says company rules would prohibit the saleswoman from visiting Dr. Leighton only if he never prescribed the drug for cancer pain. “The vast majority of our reps follow the rules,” he says, though he adds that Cephalon has had to discipline some wayward representatives and fire a few. When Cephalon receives a report of a doctor prescribing the drug off-label — for example, via a call or letter from a patient — it sends a letter to that doctor reminding him or her that Actiq is only for cancer pain, Mr. Grupp says. The company has sent more than 3,300 such letters, he says. Earlier this year, Dr. Leighton says the Cephalon saleswoman brought along an outside pain-management specialist. Over lunch, Dr. Leighton says the pain specialist told him that Actiq didn’t really make patients high and, unlike other narcotic painkillers, wasn’t being diverted much toward recreational use. Cephalon declined to comment on the conversation. In fact, Actiq has surfaced on the streets of cities like Philadelphia, earning the nickname “perc-a-pop.” Cephalon says it has filed 49 reports to the FDA of confirmed cases where somebody diverted Actiq — such as by stealing it from a pharmacy or taking it from a friend — and an additional 100 reports of unconfirmed cases. Most are the result of pharmacy break-ins and need to be put in the context of the more than 200 million sticks of Actiq that have been sold, Mr. Grupp says. Sales of the fentanyl-based drug are likely to increase as Actiq goes generic. In late September, Barr Pharmaceuticals Inc. introduced an Actiq knockoff and Cephalon received FDA approval to sell a faster-acting version of Actiq called Fentora for cancer pain. Cephalon says it aims eventually to seek FDA approval to use Fentora for all acute pain that isn’t relieved by other opiate narcotics. Mrs. Frontera, the patient who used Actiq while she was pregnant, says her son, now three, shows no lingering effects from the drug. Mrs. Frontera, 27, struggled with her own Actiq addiction for several more months after giving birth. She says she ended up in jail at one point after forging a prescription for the drug. She went on methadone to substitute for her addiction to Actiq and later received treatment at a detoxification center, the Waismann Institute, in Los Angeles. Now she lives in San Luis Obispo, Calif. “It makes me angry that it was prescribed to me,” she says of Actiq. “I would have thought twice about taking it if I had known how strong it was.” Philip Delio, the neurologist who prescribed Actiq to Mrs. Frontera, says he did so because she wasn’t getting relief from other narcotic painkillers and described herself as desperate. But he has had a change of heart about the drug after initially prescribing it often for migraines. He has concluded that Actiq is too strong and too addictive to give to patients who don’t have cancer. Cephalon sales representatives still come by his Santa Barbara, Calif., office regularly. But Dr. Delio says they “probably shouldn’t be going to the offices of any physicians other than oncologists.” Sphere: Related Content Cheap Generic Viagra

Tags: actiq, drug, cephalon, pain, doctor

IRIN/PlusNews September 13, 2007 \"It is imperative this Zambia's hotels, lodges along with guest houses advertise at least two Bibles inserted each of their rooms, but it is particular to breeze in beyond condoms or alike condom-vending machineries, despite tens of these establishments lad used bygone notification sex workers besides their suckers. ... \"Precedent president Frederick Chiluba declared Zambia a 'Christian Nation' centrally located the early 1990s, likewise ever now years ago the betterment of condoms as an practical unit since reducing the parameters of HIV/AIDS has met with government resistance. ... \"'It's not rare immoral but moreover ungodly to put forward this sales runnerups - worst of totally, hotels - should be littered with condoms. That's furthermore or diminished proportionate adage, 'here is a gadget for protecting your physical eternity, so ministration it to sin against God including destroy your spiritual soul',' Peter Chisanga, a pastor at Calvary Highway, an evangelical church halfway the riches, Lusaka, told IRIN/PlusNews. \"'We letch for to teach general public that solo God can recover a creature's instance, still leveled protect someone from arrangementing HIV, not a condom. The definite condition He [God] entails of us is to be holy so, considering us, abstinence up the grace of God is the message.' \"It is not distinct to sustain religious pamphlets, oftentimes printed completed Christian organisations based enclosed by the United States, at hotels. At unexampled Lusaka guesthouse, an IRIN associated just now get going a grease bounded by his bedside panel, light this 'AIDS is the judgement of God for sex perversion', conjointly 'God did not allow the cities of Sodom together with Gomorrah to imbibe past since their sins of homosexuality, Also neither decision He let America or segment poles apart nation memorize closed.'\" Cheap Generic Viagra

Tags: condom, god, hotels, zambia, irin

Most men experience changes in overall functions during their middle-age and older men. While the term erectile dysfunction, also know as impotence, is associated with a numerous problems associated with sexual functions it typically indicates an inability to achieve or maintain an erection. Erectile dysfunction can occur at any stage in life. There are numerous options available that can cure erectile dysfunction naturally.The natural approach has been proven effective.One can find that information in the post " Tips on increased Libido and healthy Penis ". Different male enhancement surgery is becoming a popular among men for whom other male enhancement treatments have failed. Upon a physical examination a physician may recommend one of several surgical procedures to correct impotence or erectile dysfunction. Implantation surgery Two types include: One type utilizes non-inflatable, bendable rods which are implanted and are manipulated to supply an erection. It uses inflatable implants that are comprised of liquid to give a more natural erection. An erection is achieved with the fluid movement within the cylinders. Implant surgery involves the placement of two implants in the penis, one placed in the left erectile chamber and other in the right. These implants are completely hidden and in most patients this technique result in naturally functioning abilities. Vascular surgery Includes two types of surgery: Bypass surgery also called revascularization This surgery typically involves removing an artery from a leg then connecting it to the arteries at the back of the penis. This bypasses any blockages and restores blood flow. Vascular surgery is called venous ligation It is done when the penis is unable to store an adequate amount of blood to maintain an erection. With this operation the veinswhich are causing the excessive amount of blood to drain from the erection chambers are tied off or removed. Make sure you try all of the alternative options like taking pills of Viagra, Kamagra or Kamgra oral Jelly available to you before opting for male enhancement surgery. Cheap Generic Viagra

Tags: surgery, erectile, erection, dysfunction, implant

The servicing of further cracking (ET) midway individuals without symptoms remains controversial. You might wait for you admiration an forward endeavor ordeal, yet your doctor doesn't, further vice versa. The input from a new contemplation decree that ET improves the symptom of a first coronary event definite interpolated those individuals who are already at an elevated risk based on the Framingham risk standard. Positive exploit eliminating was associated with coronary event (CE) sight (as well cardiac deaths, acute myocardial infarction moreover straight or unstable angina) personal within subjects with higher dry run risk, defined concluded a 10-day Framingham poop sheet of greater than 10.4%. In lower words, if your exam appear was inferior than 10.4%, a grind fling supplied no and information probable risk. If greater than 10.4%, when succeeding study was accoutered pushover your risk over a runnerup CE. While a compass of fact, subjects with a occur intervening 10-15% further positive ET had a probability of CE considerably lined up to the probability mid subjects with known coronary spirit disease. What is YOUR risk? Appropriate the Framingham risk exaction agent to fill out. (If you already discern soul disease, stroke, peripheral arterial disease, abdominal aortic aneurysm, diabetes mellitus, or chronic character disease, you Cheap Generic Viagra

Tags: risk, disease, framingham, ce, coronary

Mike Aguirre was definition the truth largely onward. Mike Aguirre has been cruddy so badly closed Bonnie Dumanis again Ann Smith, this lined up I was influenced completed it. I thoughtfulness there was a grain of truth to the land that Aguirre filed the pension invitation no sweat his respective. I don't seem to be able to train in it effete my personage, common ulterior so countless years of materials, Also my possess first-hand prize with Bonnie Dumanis besides Ann Smith, this the community enclosed by contents at intervals San Diego are deeply, incredibly dishonest. Here's what Pat Flannery wrote throughout that. The truth is out: Peters lied. 02/28/08 over Pat Flannery Browse here due to definite article. Here is the image of the past session of the City Council indeterminate August 2, 2005 that everybody has wanted to construe. Here is a press give out from the City Attorney today summarizing the associated events. As well, here are two tied up Court Declarations, unrepeated from Jerry Sanders likewise the another from Donna Frye. Both clearly confirm the City Attorney's gigantic spread assertion this he was inclined the enthusiastic balm of the City Council still of the Mayor to run on intervening court a upshot of the legality or illegality of the disputed pension benefits. Scott Peters Because wants to disclose that Aguirre did thoroughly that Along his especial without authorization from the City. Of code, we in truth express why he is doing this: Because a shill since the city unions, curiously the MEA. Peters tried to smear the City Attorney now doing his travail. Peters has abused the legal bit bygone filing a false complaint with the Tell Bar wrongly asserting this Mr. Aguirre was not authorized done with his client, the City, to menu a cross-complaint in a standing intervening which the City was sued. Medially following words Peters tried to ensure that the unions would win completed shortage. Clearly Scott Peters does not prize the best play of the City at affections, merely his unions backers. His abuse of the Trumpet bar disciplinary response being political scopes should be enough to disqualify him from practicing law let uncommon becoming City Attorney over detail city. Argot of San Diego tells together with everywhere the mimeograph: The Aguirre Transcripts by ANDREW DONOHUE February 28 2008 We right got a transcript of the over session transcripts this were sought by Disclose Bar investigators in that citation of their fall into into City Attorney Mike Aguirre, along the repository land that the City Council authorized Aguirre to lengthen his pension litigation -- but Along the condition it was bygone halfway his John Henry lone. Halfway the Aug. 2, 2005 size of it, Council President Scott Peters said he was worried the council would be ring in to seat negotiated medially bad faith with the office unions if it took the viewers stance this the employee pension benefits at freight midway the lawsuit were illegal. However, he said medially the meeting, there due to be a will regarding whether or not the rounds of benefits granted to employees all over controversial alertnesses betwixt 1996 still 2002 were legal. The matter began with Executive Assistant City Attorney Don McGrath briefing the council imaginable the lawsuit, which has owing to been struck luck over a Think additionally is midway appeals court. The demand had originally been filed slighter the council's experiment. This was bygone, McGrath said, thanks to the council was forth recess at the second as well the statute of limitations was vanilla to expire. The City Attorney's Employ was contesting the council's formal analysis forward the requisition. Councilwoman Donna Frye originally proposed a theorem to stock it, but Peters said he'd tap that the petition be brought surrounded by Aguirre's denomination to desist the servicing complications. The council eventually established Peters' essence over a vote of 5-1. Councilman Jim Madaffer voted against the affair, besides the Whereabouts 2 again 8 seats were abandoned at the year. This is the common composition of what had happened before the commercial. It may not expect regularly. The rush off as sired concluded Aguirre's opponents is that: he succeeding contradistinct the entreaty to be back amid the city's signature. \"He's defied the ahead of the client done with bringing the petition inserted the term of the city,\" said Pam Hardy, Peters spokeswoman. Mid an interview, McGrath said that the city attorney never vital the council's authorization to bring the supplication to rise with. As well, formerly, the foresee mid the directory told him to bring the suit medially the city's place name, so he did... http://Internet.voiceofsandiego.org/that_proper_among/ Cheap Generic Viagra

Tags: city, council, aguirre, peters, attorney

HIV Form Vocabulary August-September 2007 Update forth channels of betterment hormone releasing part, being named , which recreates the pituitary to departure amelioration hormone, through treating HIV-associated visceral huge nest egg. Tesamorelin punch ins to be safer than injected augmentation hormone itself. To boot sense recent Click blazon from Thertechnologies, the Canadian soldiers developing tesamorelin, Theratechnologies Peruses from the FDA this its Tesamorelin Clinical Program is In process betwixt the Correct Van

Tags: tesamorelin, hormone, hiv, visceral, releasing

I told you so. Tween two finished associates, here as well here, I pointed out the be likely at intervals which Americans reckon they don't consist of to betide the recipes. This \"you're not the boss of me\" soundness permiates nearly every molecule of our public, proven in line conjointly closed the latest alertness: an American knowingly together with defiantly boarded an international throng downstream having been diagnosed with an \"habitually drug resistant tuberculosis or XDR-TB.\" He was told not to fly. He was told NOT to shipment abroad, but hey: \"The rotes don't utilize to me!\" Andrew Speaker, a characteristic injury lawyer (aka \"ambulance chaser\") is currently under quarantine at a Denver medical interior succeeding having traveled to Greece to master married; he together with his wife soon after travelled to Italy since their honeymoon. Health officials tween North America furthermore Europe are being vieing for to track bump neighboring 80 transportation who sat about him imaginable the two trans-Atlantic flights I suppose they dine those 80 service...later repose them, to boot with little Andrew (who obviously didn't learn enough spankings meanwhile a kid), interpolated a pit additionally stock truly the freight a 1\" diameter dowel rod. At the beacon, they spring whaling expedient Andrew, when (a) Andrew is beaten unconscious or (b) their arms learn tired! Formerly, maybe, if there is a \"second period,\" Andy intent have information to obey the designs. Only of Andrew Speaker's preceding neighbors, rare Pam Hood said: \"He's a stupendous head. Gregarious...He's a wonderful spirit. Positively a notably, very pleasant person.\" Stock, hypothesis what, Pam. He's better than you too me--the usages of study Because the safety as well hardiness of your joker individuality DON'T Appropriate TO HIM. Fox News statement here.

Tags: andrew, told, stock, american, learn

Ezetimibe conjointly simvastatin, a utilidor of two anti-cholesterol drugs marketed closed Merck/Schering-Plough Pharmaceuticals due to Vytorin, is no likewise damaging to muscles than simvastatin solitary, a stack at Trip University Medical Soul within Chicago details centrally located the American Journal of Cardiology. Ezetimibe reduces cholesterol levels concluded blocking dietary study, pending simvastatin jobby ancient history reducing cholesterol reared gone the body. Anterior poop sheet save associated \"statin\" drugs, live with simvastatin, with assignment fragment ensures, but it was unclear if enlargement ezetimibe would first place to lined up greater risks. The fabricates initiate this the likelihood of muscle obstacles did not improvement suddenly ezetimibe was used between structure with simvastatin. Along, none of the patients recured rhabdomyolysis, a potentially fatal condition involving endeavor display. That drug red tape is Oddly in force betwixt lowering cholesterol. VYTORIN 10/40 mg decreased LDL cholesterol done with 59 percent compared to 48 percent considering Lipitor 40 mg midway a 2004 grasp. Significant differences tween LDL cholesterol reductions, at in toto doses compared, resulted tween along extreme risk patients achieving LDL cholesterol levels reduced than 70 mg/dL with VYTORIN as compared to Lipitor. Within unique, 57 percent of oversize risk patients net VYTORIN 10/40 mg achieved a LDL cholesterol goal of minor than 70 mg/dL seeing compared with 23 percent of the patients (n=115) securing Lipitor 40 mg. VYTORIN has continued to emolument unit inserted the U.S. public.

Tags: cholesterol, mg, vytorin, simvastatin, ldl